180 related articles for article (PubMed ID: 33082307)
1. EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal.
Paredes R; Kelly JR; Geary B; Almarzouq B; Schneider M; Pearson S; Narayanan P; Williamson A; Lovell SC; Wiseman DH; Chadwick JA; Jones NJ; Kustikova O; Schambach A; Garner T; Amaral FMR; Pierce A; Stevens A; Somervaille TCP; Whetton AD; Meyer S
Cell Death Dis; 2020 Oct; 11(10):878. PubMed ID: 33082307
[TBL] [Abstract][Full Text] [Related]
2. EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.
Paredes R; Schneider M; Stevens A; White DJ; Williamson AJK; Muter J; Pearson S; Kelly JR; Connors K; Wiseman DH; Chadwick JA; Löffler H; Teng HY; Lovell S; Unwin R; van de Vrugt HJ; Smith H; Kustikova O; Schambach A; Somervaille TCP; Pierce A; Whetton AD; Meyer S
Nucleic Acids Res; 2018 Sep; 46(15):7662-7674. PubMed ID: 29939287
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability.
White DJ; Unwin RD; Bindels E; Pierce A; Teng HY; Muter J; Greystoke B; Somerville TD; Griffiths J; Lovell S; Somervaille TC; Delwel R; Whetton AD; Meyer S
PLoS One; 2013; 8(6):e66510. PubMed ID: 23776681
[TBL] [Abstract][Full Text] [Related]
4. EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle.
Paredes R; Schneider M; Pearson S; Teng HY; Kelly JR; Pierce A; Somervaille TCP; Whetton AD; Meyer S
Mol Biol Rep; 2020 Oct; 47(10):8293-8300. PubMed ID: 32979164
[TBL] [Abstract][Full Text] [Related]
5. Oncogene
Pastoors D; Havermans M; Mulet-Lazaro R; Brian D; Noort W; Grasel J; Hoogenboezem R; Smeenk L; Demmers JAA; Milsom MD; Enver T; Groen RWJ; Bindels E; Delwel R
Sci Adv; 2024 May; 10(20):eadk9076. PubMed ID: 38748792
[TBL] [Abstract][Full Text] [Related]
6. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
Lugthart S; Figueroa ME; Bindels E; Skrabanek L; Valk PJ; Li Y; Meyer S; Erpelinck-Verschueren C; Greally J; Löwenberg B; Melnick A; Delwel R
Blood; 2011 Jan; 117(1):234-41. PubMed ID: 20855866
[TBL] [Abstract][Full Text] [Related]
7. The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA.
Senyuk V; Premanand K; Xu P; Qian Z; Nucifora G
PLoS One; 2011; 6(6):e20793. PubMed ID: 21695170
[TBL] [Abstract][Full Text] [Related]
8. EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
Paredes R; Doleschall N; Connors K; Geary B; Meyer S
Exp Hematol; 2022 Mar; 107():1-8. PubMed ID: 34958895
[TBL] [Abstract][Full Text] [Related]
9. Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis.
Kataoka K; Kurokawa M
Cancer Sci; 2012 Aug; 103(8):1371-7. PubMed ID: 22494115
[TBL] [Abstract][Full Text] [Related]
10. EVI1 drives leukemogenesis through aberrant ERG activation.
Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
[TBL] [Abstract][Full Text] [Related]
11. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
13. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
[TBL] [Abstract][Full Text] [Related]
14. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms].
Tanaka A
Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237
[TBL] [Abstract][Full Text] [Related]
15. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.
Yamakawa N; Kaneda K; Saito Y; Ichihara E; Morishita K
PLoS One; 2012; 7(1):e30706. PubMed ID: 22295105
[TBL] [Abstract][Full Text] [Related]
16. Evi1 upregulates Fbp1 and supports progression of acute myeloid leukemia through pentose phosphate pathway activation.
Mizuno H; Koya J; Masamoto Y; Kagoya Y; Kurokawa M
Cancer Sci; 2021 Oct; 112(10):4112-4126. PubMed ID: 34363719
[TBL] [Abstract][Full Text] [Related]
17. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
18. Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1.
Laricchia-Robbio L; Nucifora G
Blood Cells Mol Dis; 2008; 40(2):141-7. PubMed ID: 17913523
[TBL] [Abstract][Full Text] [Related]
19. Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.
Li F; He W; Geng R; Xie X
Clin Transl Oncol; 2020 Jan; 22(1):137-143. PubMed ID: 31054042
[TBL] [Abstract][Full Text] [Related]
20. Review: Aberrant EVI1 expression in acute myeloid leukaemia.
Hinai AA; Valk PJ
Br J Haematol; 2016 Mar; 172(6):870-8. PubMed ID: 26729571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]